AngioDynamics (NASDAQ:ANGO) Issues FY 2027 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) updated its FY 2027 earnings guidance on Thursday morning. The company provided EPS guidance of -0.290–0.240 for the period, compared to the consensus earnings per share estimate of -0.260. The company issued revenue guidance of $336.0 million-$341.0 million, compared to the consensus revenue estimate of $337.6 million.

Analyst Ratings Changes

Several equities analysts recently issued reports on ANGO shares. HC Wainwright lifted their price objective on shares of AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. Zacks Research upgraded AngioDynamics from a “strong sell” rating to a “hold” rating in a report on Monday. Canaccord Genuity Group boosted their price target on AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Finally, Wall Street Zen upgraded AngioDynamics from a “hold” rating to a “buy” rating in a research note on Saturday, August 22nd. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $19.50.

AngioDynamics Stock Down 1.6%

Shares of ANGO opened at $14.19 on Thursday. The company has a market cap of $596.69 million, a price-to-earnings ratio of -16.31 and a beta of 0.30. AngioDynamics has a twelve month low of $9.39 and a twelve month high of $16.29. The company has a 50 day moving average of $15.46 and a two-hundred day moving average of $13.11.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.The business had revenue of $80.92 million for the quarter, compared to the consensus estimate of $80.51 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, sell-side analysts expect that AngioDynamics will post -0.25 EPS for the current year.

Insider Transactions at AngioDynamics

In other AngioDynamics news, SVP Warren Jr sold 23,370 shares of the stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the sale, the senior vice president directly owned 64,745 shares in the company, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 6.00% of the stock is owned by corporate insiders.

Key Stories Impacting AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Quarterly results exceeded expectations: AngioDynamics reported revenue of $80.9 million, above the $80.5 million consensus estimate, while adjusted EPS of $(0.04) beat expectations of $(0.11). Revenue increased 6.9% year over year, and the GAAP net loss narrowed to $7.1 million from $10.9 million. AngioDynamics Fiscal 2027 First-Quarter Financial Results
• Positive Sentiment: Medical technology growth was strong: Med Tech sales rose 13.2% to $39.9 million, led by Auryon sales growth of 14.7% and NanoKnife sales growth of 29.0%. Gross margin also expanded 410 basis points to 59.4%, indicating improved operating performance.
• Positive Sentiment: Pipeline and leadership developments may support the outlook: The FDA approved an IDE for a NanoKnife feasibility study in benign prostatic hyperplasia, while Eric Honroth is set to become president and CEO on November 2, 2026. CEO Appointment
• Neutral Sentiment: Full-year guidance was reiterated: Fiscal 2027 revenue is expected at $336 million to $341 million, slightly above the $337.6 million analyst consensus at the midpoint. EPS guidance of $(0.29) to $(0.24) is broadly in line with the $(0.26) consensus estimate.
• Negative Sentiment: Profitability and liquidity remain risks: The company still reported a GAAP loss, negative net margin and negative return on equity. It used $15.3 million in operating cash during the quarter, leaving $34.0 million in cash at August 31.
• Negative Sentiment: Insider selling may temper sentiment: A senior vice president sold 23,370 shares for approximately $344,000, with no reported insider purchases during the past six months.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.